1993
DOI: 10.1182/blood.v81.10.2696.2696
|View full text |Cite
|
Sign up to set email alerts
|

DCC tumor suppressor gene is inactivated in hematologic malignancies showing monosomy 18

Abstract: DCC (deleted in colorectal cancer) is a candidate tumor suppressor gene recently identified on chromosome band 18q21. Loss of one DCC allele or decreased DCC expression occurs in more than 70% of colorectal cancers, suggesting that DCC inactivation constitutes a critical event in the development of these tumors. Using polymerase chain reaction amplification of cDNA, we have studied DCC expression in bone marrow from 4 patients with leukemia (1 chronic myeloid leukemia-blastic crisis, case 1; 1 acute myeloid le… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
4
0

Year Published

1995
1995
2016
2016

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 39 publications
(6 citation statements)
references
References 15 publications
2
4
0
Order By: Relevance
“…The same abnormalities were found in three additional cases of the present series (8p21 in case nos 14 and 23; 19q13 in case nos 14 and 15). Gains or losses involving chromosome 18, which is known to be associated with inactivation of the DCC tumour-suppressor gene (Porfiri et al, 1993;Hamaguchi et al, 1998), also appeared to be common in both of the present series (75%) and those reported by Shimazaki et al (1999)…”
Section: Discussionsupporting
confidence: 67%
“…The same abnormalities were found in three additional cases of the present series (8p21 in case nos 14 and 23; 19q13 in case nos 14 and 15). Gains or losses involving chromosome 18, which is known to be associated with inactivation of the DCC tumour-suppressor gene (Porfiri et al, 1993;Hamaguchi et al, 1998), also appeared to be common in both of the present series (75%) and those reported by Shimazaki et al (1999)…”
Section: Discussionsupporting
confidence: 67%
“…The same abnormalities were found in three additional cases of the present series (8p21 in case nos 14 and 23; 19q13 in case nos 14 and 15). Gains or losses involving chromosome 18, which is known to be associated with inactivation of the DCC tumour‐suppressor gene (Porfiri et al , 1993; Hamaguchi et al , 1998), also appeared to be common in both of the present series (75%) and those reported by Shimazaki et al (1999) (71%).…”
Section: Discussionsupporting
confidence: 62%
“…The observation that DCC expression was lost/reduced in colorectal cancer suggested that DCC presence is a negative constraint for tumor development. Along this line, LOH of chromosome 18q and/or decreased DCC expression have also been detected in various other cancers, including gastric (Uchino et al, 1992) (Fang et al, 1998) (Yoshida et al, 1998), prostate (Brewster et al, 1994) (Latil et al, 1994) (Latil et al, 2003), endometrial (Imamura et al, 1992) (Gima et al, 1994) (Saegusa et al, 1999), ovarian (Enomoto et al, 1995) (Saegusa et al, 2000), esophageal (Huang et al, 1992) (Dolan et al, 1998), breast (Devilee et al, 1991) (Thompson et al, 1993), testicular (Murty et al, 1994) (Strohmeyer et al, 1997), glial (Scheck andCoons, 1993) (Reyes-Mugica et al, 1997), neuroblastoma (Kong et al, 1997) (Reyes-Mugica et al, 1998, and hematologic (Porfiri et al, 1993) (Miyake et al, 1993) (Miyake et al, 1994) malignancies. In most of studies, chromosome 18q LOH and loss of DCC expression have been associated with poor prognosis in colorectal cancer patients (Jen et al, 1994) (Lanza et al, 1998) (Sun et al, 1999) (Saito et al, 1999) (Saw et al, 2002) and with decreased responsiveness to chemotherapeutic agent like 5-fluorouracil-based adjuvant (Barratt et al, 2002).…”
Section: Netrin-1 and Its Receptorsmentioning
confidence: 99%